Loading...


*  Biomolecules | Free Full-Text | Is Cell Death Primary or Secondary in the Pathophysiology of Idiopathic Parkinson's Disease?
... it is quite evident that the death of dopaminergic neurons is a secondary event in the pathophysiology of Parkinson's disease. ... In consequence, neuron loss was thought to be the primary step in the neurodegeneration in Parkinson's disease. On the other ... These findings may fundamentally change the pathophysiological concept of Parkinson's disease: not nerve cell loss, but the ... In the final stage of the disease, there is a marked loss of neurons in the substantia nigra. In addition, Lewy bodies can be ...
  http://www.mdpi.com/2218-273X/5/3/1467
*  Parkinson Disease, Secondary; Atherosclerotic Parkinsonism; Secondary Parkinsonism; Symptomatic Parkinson Disease
Secondary; Atherosclerotic Parkinsonism; Secondary Parkinsonism; Symptomatic Parkinson Disease. On-line free medical diagnosis ... Ranked list of possible diseases from either several symptoms or a full patient history. A similarity measure between symptoms ... Parkinson Disease, Secondary (Atherosclerotic Parkinsonism; Secondary Parkinsonism; Symptomatic Parkinson Disease). Conditions ... "Parkinson Disease, Secondary"Drugs, active principles and "Parkinson Disease, Secondary"Medicinal plantsQuestions and answers ...
  https://lookfordiagnosis.com/mesh_info.php?term=Parkinson+Disease%2C+Secondary&lang=1
*  Study of Memantine for Gait Disorders And Attention Deficit In Parkinson's Disease
... see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are ... Parkinson Disease, Secondary. Conditions which feature clinical manifestations resembling primary Parkinson disease that are ... PARKINSON DISEASE, SECONDARY). MPTP toxicity is also used as an animal model for the study of PARKINSON DISEASE. (Adams et al ... To evaluate the effects of Memantine on non-motor symptoms in patients with Parkinson's disease. Parkinson's disease (PD) ...
  https://www.bioportfolio.com/resources/trial/65788/Study-of-Memantine-for-Gait-Disorders-And-Attention-Deficit-In-Parkinsons-Disease.html
*  Comparison of Modafinil and Methylphenidate in Treatment of Excessive Daytime Sleepiness in Patients With Parkinson's Disease
... see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are ... Parkinson Disease, Secondary. Conditions which feature clinical manifestations resembling primary Parkinson disease that are ... PARKINSON DISEASE, SECONDARY). MPTP toxicity is also used as an animal model for the study of PARKINSON DISEASE. (Adams et al ... Parkinson's disease with excessive daytime sleepiness.. Description. Sleep disorders are common in Parkinson's disease (PD) and ...
  https://www.bioportfolio.com/resources/trial/103991/Comparison-of-Modafinil-and-Methylphenidate-in-Treatment-of-Excessive-Daytime-Sleepiness-in.html
*  Compound Report Card
Parkinson Disease, Secondary. D010302. EFO:1001175. secondary Parkinson disease. 4. DailyMed. DailyMed. DailyMed. DailyMed. ... Parkinson Disease. D010300. EFO:0002508. Parkinson's disease. 4. ATC. ClinicalTrials. DailyMed. DailyMed. DailyMed. DailyMed. ... Parkinson Disease, Postencephalitic. D010301. EFO:1001402. postencephalitic Parkinson disease. 4. DailyMed. DailyMed. DailyMed ... N04 - ANTI-PARKINSON DRUGS. N04B - DOPAMINERGIC AGENTS. N04BB - Adamantane derivatives. N04BB01 - amantadine. ...
  https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL660
*  Are men at greater risk for Parkinson's disease than women? | Journal of Neurology, Neurosurgery & Psychiatry
Vines JJ, Larumbe R, Gaminde I, et al. Incidence of idiopathic and secondary Parkinson's disease in Navarre. Neurologia 1999;14 ... Parkinson's disease seems to occur more commonly in men than women based primarily on studies of death rates and prevalence. In ... Wang YS, Shi YM, Wu ZY, et al. Parkinson's disease in China. Coordinated Group of Neuroepidemiology, PLA. Chinese Med J 1991; ... Granieri E, Carresas M, Casetta I, et al. Parkinson's disease in Ferrara, Italy, 1967-1987. Arch Neurol 1991;48:854-7. ...
  http://jnnp.bmj.com/content/75/4/637.full
*  Transcranial Duplex Scanning and Single Photon Emission Computer Tomography (SPECT) in Parkinsonian Syndromes - Full Text View ...
Parkinson Disease, Secondary. Disease. Pathologic Processes. Basal Ganglia Diseases. Brain Diseases. Central Nervous System ... MedlinePlus related topics: Nuclear Scans Parkinson's Disease Genetic and Rare Diseases Information Center resources: ... Vascular Diseases. Cardiovascular Diseases. Ophthalmoplegia. Ocular Motility Disorders. Cranial Nerve Diseases. Tauopathies. ... in patients suspected of having Idiopathic Parkinson Disease (PD) or Atypical Parkinson Syndromes (APS) with as golden standard ...
  https://clinicaltrials.gov/ct2/show/NCT00368199
*  Dr. Danny Benmoshe MD Reviews | West Hollywood, CA | Vitals.com
Alzheimer's Disease * Parkinson Disease * Essential Tremor * Secondary Parkinson Disease * Diabetic Neuropathies * Headache ... Parkinson's disease, multiple sclerosis, stroke, spinal disc herniation, and spinal disease. In addition to using diagnostic ...
  https://www.vitals.com/doctors/Dr_Danny_Benmoshe.html
*  Naltrexone for Impulse Control Disorders in Parkinson's Disease
... clinicaltrials.gov This study will evaluate the effectiveness of naltrexone in reducing ICD symptoms in Parkinson ... see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are ... Induced by Dopaminergic Treatments in Parkinson's Disease. Impulse control disorders encountered in Parkinson's disease (PD) ... Parkinson's Disease Parkinson's is a progressive neurological condition, affecting one person in every 500, 95% of which are ...
  https://www.bioportfolio.com/resources/trial/68758/Naltrexone-for-Impulse-Control-Disorders-in-Parkinsons-Disease.html
*  Methylphenidate and Parkinson's Disease
... see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are ... Parkinson Disease, Secondary. Conditions which feature clinical manifestations resembling primary Parkinson disease that are ... Ophthalmic disorders as a manifestation of Parkinson's disease.. Parkinson's disease is a severe neurodegenerative disease ... PARKINSON DISEASE, SECONDARY). MPTP toxicity is also used as an animal model for the study of PARKINSON DISEASE. (Adams et al ...
  https://www.bioportfolio.com/resources/trial/105801/Methylphenidate-and-Parkinsons-Disease.html
*  OPUS at UTS: Activin A protects midbrain neurons in the 6-hydroxydopamine mouse model of Parkinson's disease. - Open...
Parkinson Disease, Secondary. en_US. dc.subject.mesh. Disease Models, Animal. en_US. ... Parkinson's disease (PD) is a chronic neurodegenerative disease characterized by a significant loss of dopaminergic neurons ... Parkinson's disease (PD) is a chronic neurodegenerative disease characterized by a significant loss of dopaminergic neurons ... Activin A protects midbrain neurons in the 6-hydroxydopamine mouse model of Parkinson's disease.. Stayte, S Rentsch, P Li ...
  https://opus.lib.uts.edu.au/handle/10453/95324
*  Parkinson's Disease A Guide to Patient Care-9780826122681|Springer Publishing Company
... this book covers all aspects of effectively managing patients with Parkinson's disease, with discussio ... Parkinson's Disease,'As a quick, user-friendly reference, ... prescribed to treat secondary symptoms of Parkinson's disease. ... Agents Contraindicated in Parkinson's disease. Medications that block or decrease dopamine and can worsen Parkinson symptoms. ... Parkinson Disease Rating Scales. Sleep Studies. Speech Evaluation. Swallowing Evaluation. Urological Testing in Parkinson's ...
  http://www.springerpub.com/parkinson-s-disease.html
*  Herbal Materia Medica: Ginkgo Biloba
in Parkinson's disease secondary to cerebral arteriosclerosis, the herb increased blood supply to the brain. * 65% successful ... 8A Unified Theory of Human Cardiovascular Disease Leading the Way to the Abolition of This Disease as a Cause for Human ... Concerning Alzheimer's disease and dementia, no firm conclusion can be drawn for the time being due to the lack of animal model ... Raynaud's disease: cerebral vascular and nutritional insufficiency * hormonal and neural based disorders as well as angiopathic ...
  http://www.healthy.net/Health/Article/Ginkgo_Biloba/1169/
*  Herbal Materia Medica: Ginkgo Biloba
in Parkinson's disease secondary to cerebral arteriosclerosis, the herb increased blood supply to the brain. * 65% successful ... Concerning Alzheimer's disease and dementia, no firm conclusion can be drawn for the time being due to the lack of animal model ... Raynaud's disease: cerebral vascular and nutritional insufficiency * hormonal and neural based disorders as well as angiopathic ... However, experimental data suggest that the product may act on a number of major elements of these diseases. From what is ...
  http://www.healthy.net/scr/article.aspx?Id=1169
*  Apomorphine | definition of apomorphine by Medical dictionary
Sunovion Apomorphine Sublingual Film Meets Primary and Secondary Endpoints in Parkinson's Disease Patients ... A poisonous alkaloid, C17H17NO2, that is an analog of morphine and is used medicinally to treat Parkinson's disease and to ... Used in the treatment of Parkinson's disease. Brand names are Apo-go and Uprima.. apomorphine. an alkaloid from morphine. Used ... Neurotoxicity of the Parkinson disease-associated pesticide Ziram is synuclein-dependent in zebrafish embryos ...
  https://medical-dictionary.thefreedictionary.com/apomorphine
*  Effects of Melatonin Levels on Neurotoxicity of the Medial Prefrontal Cortex in a Rat Model of Parkinson's Disease. - Free...
Effects of Melatonin Levels on Neurotoxicity of the Medial Prefrontal Cortex in a Rat Model of Parkinson's Disease.(Original ... Primary and secondary features of Parkinson's disease improve with strategic exposure to bright light: A case series study. ... Parkinson's disease (PD) is a neurodegenerative disease, where the reduction of dopamine (DA) in the substantia nigra pars ... MLA style: "Effects of Melatonin Levels on Neurotoxicity of the Medial Prefrontal Cortex in a Rat Model of Parkinson's Disease ...
  https://www.thefreelibrary.com/Effects+of+Melatonin+Levels+on+Neurotoxicity+of+the+Medial+Prefrontal+...-a0514482209
*  Collagen Limits Voice Disorder in Parkinson's. (Simple Office Procedure). - Free Online Library
... general Health aspects Parkinson disease Complications Parkinson's disease Speech disorders Care and treatment ... Collagen Limits Voice Disorder in Parkinson's. (Simple Office Procedure). by 'Internal Medicine News'; Health care industry ... She reported on 18 patients with voice problems secondary to Parkinson's disease. All had incomplete glottic closure on maximal ... Hunt intensifies for Parkinson's gene.. Getting on our nerves: researchers find a connection between Parkinson's Disease and ...
  https://www.thefreelibrary.com/Collagen+Limits+Voice+Disorder+in+Parkinson%27s.+
*  Parkinson's disease and parkinsonism - ONA
A diagnosis of idiopathic Parkinson's disease requires ruling out secondary causes. Medications must be reviewed for possible ... Parkinson's disease and Parkinsonism. I. What every physician needs to know.. Idiopathic Parkinson's disease is a progressive ... which are a hallmark finding of Parkinson's disease. Idiopathic Parkinson's disease is a clinical diagnosis of exclusion. ... Patients with Parkinson's disease can easily become deconditioned. Short term rehab can be of benefit, and there are some ...
  https://www.oncologynurseadvisor.com/hospital-medicine/parkinsons-disease-and-parkinsonism/article/600103/
*  Terapija s svetlobo - Wikipedija, prosta enciklopedija
Willis GL, Turner EJ (2007). "Primary and secondary features of Parkinson's disease improve with strategic exposure to bright ... Paus S, Schmitz-Hübsch T, Wüllner U, Vogel A, Klockgether T, Abele M (2007). "Bright light therapy in Parkinson's disease: a ... Paus S et alii:Brigt light therapy in Parkinson's disease:a pilot study. Mov Disord. 2007 Jul 30;22(10):1495-8. ... Paus S et alii:Brigt light therapy in Parkinson's disease:a pilot study. Mov Disord. 2007 Jul 30;22(10):1495-8. ...
  https://sl.wikipedia.org/wiki/Terapija_s_svetlobo
*  Parkinson's Disease and Cryptogenic Epilepsy
Open Access journal that publishes case reports focusing on diseases of the nervous system, as well as abnormal neurological ... W. J. Schulz-Schaeffer, "Is cell death primary or secondary in the pathophysiology of idiopathic Parkinson's disease?" ... Parkinson's Disease and Cryptogenic Epilepsy. Andre Y. Son,1 Milton C. Biagioni,1 Dorian Kaminski,1 Alec Gurevich,1 Britt Stone ... "Staging of brain pathology related to sporadic Parkinson's disease," Neurobiology of Aging, vol. 24, no. 2, pp. 197-211, 2003. ...
  https://www.hindawi.com/journals/crinm/2016/3745631/ref/
*  Parkinsonism - A Review - P.B. Kader - Disease Index, Homeopathy Papers, Neurological Disorders
Parkinsonism - A Review - Disease Index, Homeopathy Papers, Neurological Disorders ... It is also known as Parkinson's syndrome, atypical Parkinson's or secondary Parkinson's disease. In the initial stages, the ... Parkinson's disease is the second most common neuro-degenerative disease after Alzheimer's disease and affects approximately 1 ... As Parkinson's disease is a slowly crippling chronic disease, we have to arrest or delay its progression at an early stage. ...
  https://hpathy.com/homeopathy-papers/a-review-of-parkinsonism/
*  LRRK2-Related Parkinson Disease - GeneReviews® - NCBI Bookshelf
LRRK2-related Parkinson disease (PD) is characterized by features consistent with idiopathic PD: initial motor features of ... Prevention of secondary complications: Prevention of L-dopa induced dyskinesias may include deep-brain stimulation, constant ... LRRK2-Related Parkinson Disease. Synonyms: LRRK2-Associated Parkinson Disease, PARK8. Joanne Trinh, BSc, Matthew Farrer, PhD, ... Review PINK1 Type of Young-Onset Parkinson Disease[GeneReviews®. 1993]. Review PINK1 Type of Young-Onset Parkinson Disease. ...
  https://www.ncbi.nlm.nih.gov/books/NBK1208/
*  PINK1 Type of Young-Onset Parkinson Disease - GeneReviews® - NCBI Bookshelf
... and rigidity that are often indistinguishable from other causes of Parkinson disease. Lower-limb dystonia may be a presenting ... The disease is usually slowly progressive. Individuals have a marked and sustained response to oral administration of levodopa ... PINK1 type of young-onset Parkinson disease is characterized by early onset (mean age 33 years) of tremor, bradykinesia, ... Prevention of secondary complications: L-dopa dosage should not exceed the level required for satisfactory clinical response. ...
  https://www.ncbi.nlm.nih.gov/books/NBK26472/
*  Dopamine dysregulation syndrome - Wikipedia
... emergence secondary to treatment of Parkinson's disease with dopaminergic agents". Depress Anxiety. 11 (4): 185-6. doi:10.1002/ ... Parkinson's disease is a common neurological disorder characterized by a degeneration of dopamine neurons in the substantia ... It typically occurs in people with Parkinson's disease (PD) who have taken dopamine agonist medications for an extended period ... Lawrence AD, Evans AH, Lees AJ (October 2003). "Compulsive use of dopamine replacement therapy in Parkinson's disease: reward ...
  https://en.wikipedia.org/wiki/Dopamine_dysregulation_syndrome
*  Gene therapy in Parkinson's disease - Wikipedia
"Parkinson's disease: Diagnosis and management in primary and secondary care". National Institute for Health and Care Excellence ... In Parkinson disease, the loss of neurons from the nigrostriatum leads to the inability to convert levodopa to dopamine. The ... Parkinson's disease (PD) is a progressive neurological condition result of the death of the cell that contains and produces ... Gene therapy in Parkinson's disease consists of the creation of new cells that produce a specific neurotransmitter (dopamine), ...
  https://en.wikipedia.org/wiki/Gene_therapy_in_Parkinson's_disease